ALZN Stock Surges On Dosing Of First Human Patient With Lithium-Delivery System
Recently, Alzamend Neuro Inc. has announced its privilege of dosing the AL001 Phase II to its first patient in the clinical trial. After that, on the next morning, its stock surged 84% to $6.14, which is a big change. According to the company, AL001 is a proprietary formulation that delivers the lithium to the brain more…